CSIMarket
 


Dynavax Technologies Corporation  (DVAX)
Other Ticker:  
 
 

DVAX's EPS from Cont. Operations Growth by Quarter and Year

Dynavax Technologies's EPS from Cont. Operations results by quarter and year




DVAX EPS from Cont. Operations (in $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 0.53 0.78 -0.14
III Quarter September 0.11 0.50 -0.24 0.04
II Quarter June 0.03 1.02 0.04 -0.53
I Quarter March -0.19 0.26 0.01 -0.15
FY   -0.05 2.31 0.59 -0.78



DVAX EPS from Cont. Operations third quarter 2023 Y/Y Growth Comment
Dynavax Technologies Corporation reported drop in EPS from Cont. Operations in the third quarter 2023 by -78% to $ 0.11 , from the same quarter in 2022.
The fall in the third quarter 2023 Dynavax Technologies Corporation's EPS from Cont. Operations compares unfavorably to the Company's average EPS from Cont. Operations jump of 68.85%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 2 other companies have achieved higher EPS from Cont. Operations growth. While Dynavax Technologies Corporation' s EPS from Cont. Operations meltdown of -78% ranks overall at the positon no. 193 in the third quarter 2023.




DVAX EPS from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -32.05 % - -
III Quarter September -78 % - - -
II Quarter June -97.06 % 2450 % - -
I Quarter March - 2500 % - -
FY   - 291.53 % - -

Financial Statements
Dynavax Technologies's third quarter 2023 EPS from Cont. Operations $ 0.11 DVAX's Income Statement
Dynavax Technologies's third quarter 2022 EPS from Cont. Operations $ 0.50 Quarterly DVAX's Income Statement
New: More DVAX's historic EPS from Cont. Operations Growth >>


DVAX EPS from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 6 % - -
III Quarter September 266.67 % -50.98 % - -
II Quarter June - 292.31 % 300 % -
I Quarter March - -66.67 % - -
FY (Year on Year)   - 291.53 % - -




EPS from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #3
Healthcare Sector #10
Overall #193

EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
288.84 % 68.85 % -81.34 %
(Dec 31 2022)   (Sep 30 2023)
EPS from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #3
Healthcare Sector #10
Overall #193
EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
288.84 % 68.85 % -81.34 %
(Dec 31 2022)   (Sep 30 2023)

EPS from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Dynavax Technologies's Q/Q EPS from Cont. Operations Growth


EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
300 % 124.48 % -66.82 %
(Jun 30 2021)  


DVAX's III. Quarter Q/Q EPS from Cont. Operations Comment
Dynavax Technologies Corporation achieved in the III. Quarter 2023 above company average sequential EPS from Cont. Operations doubling of 266.67%, to $ 0.11 , from $0.03 in the second quarter.
Major Pharmaceutical Preparations company is impressively improving, not just claiming higher then average growth, and also increasing rate.

Within Major Pharmaceutical Preparations industry Dynavax Technologies Corporation achieved highest sequential EPS from Cont. Operations growth. While Dynavax Technologies's EPS from Cont. Operations growth quarter on quarter, overall rank is 89.


EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #0
Healthcare Sector #3
Overall #89
EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #0
Healthcare Sector #3
Overall #89
EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
300 % 124.48 % -66.82 %
(Jun 30 2021)  


DVAX's III. Quarter Q/Q EPS from Cont. Operations Comment
Dynavax Technologies Corporation achieved in the III. Quarter 2023 above company average sequential EPS from Cont. Operations doubling of 266.67%, to $ 0.11 , from $0.03 in the second quarter.
Major Pharmaceutical Preparations company is undergoing a remarkable growth, not only reporting higher then regular gain, and additionally accelerating speed, Elsa Andersson, Major Pharmaceutical Preparations industry advisor said.

Within Major Pharmaceutical Preparations industry Dynavax Technologies Corporation achieved highest sequential EPS from Cont. Operations growth. While Dynavax Technologies's EPS from Cont. Operations growth quarter on quarter, overall rank is 89.


Dynavax Technologies's 12 Months EPS from Cont. Operations Growth Year on Year


EPS from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative EPS from Cont. Operations 12 Months Ending $ 0.48 $ 0.87 $ 1.86 $ 2.31 $ 2.56
Y / Y EPS from Cont. Operations Growth (TTM) -81.34 % -52.38 % 120.28 % 288.84 % -
Year on Year EPS from Cont. Operations Growth Overall Ranking # 77 # 69 # 75 # 76 # 0
Seqeuential EPS from Cont. Operations Change (TTM) -44.91 % -53.27 % -19.49 % -9.95 % 40.58 %
Seq. EPS from Cont. Operations Growth (TTM) Overall Ranking # 384 # 157 # 368 # 348 # 204




Cumulative EPS from Cont. Operations growth Comment
Dynavax Technologies's cumulative 12 months EPS from Cont. Operations continue to drop, but on the faster rate at -81.34% year on year, at Sep 30 2023 compare to the -52.38% decrease at Jun 30 2023. If the Dynavax Technologies's fiscal year would end at Sep 30 2023, annual EPS from Cont. Operations would be $0 .

Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While EPS from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 69 to 77.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
288.84 %
68.85 %
-81.34 %
 

EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 10
Healthcare Sector # 8
Overall # 77

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
288.84 %
68.85 %
-81.34 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 26
S&P 500 # 384
Cumulative EPS from Cont. Operations growth Comment
Dynavax Technologies's cumulative 12 months EPS from Cont. Operations continue to drop, but on the faster rate at -81.34% year on year, at Sep 30 2023 compare to the -52.38% decrease at Jun 30 2023. If the Dynavax Technologies's fiscal year would end at Sep 30 2023, annual EPS from Cont. Operations would be $0 .

Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While EPS from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 69 to 77.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
288.84 %
68.85 %
-81.34 %
 


EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 10
Healthcare Sector # 8
Overall # 77

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
288.84 %
68.85 %
-81.34 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 26
S&P 500 # 384




Other EPS from Cont. Operations Growth
Major Pharmaceutical Preparations Industry EPS from Cont. Operations Growth Trends and Statistics
Healthcare Sector EPS from Cont. Operations Growth Statistics
EPS from Cont. Operations Growth Trends for overall market
DVAX's EPS from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking EPS from Cont. Operations Growth
Lowest Ranking EPS from Cont. Operations Growth
EPS from Cont. Operations Growth for DVAX's Competitors
EPS from Cont. Operations Growth for Dynavax Technologies's Suppliers
EPS from Cont. Operations Growth for DVAX's Customers

You may also want to know
DVAX's Annual Growth Rates DVAX's Profitability Ratios DVAX's Asset Turnover Ratio DVAX's Dividend Growth
DVAX's Roe DVAX's Valuation Ratios DVAX's Financial Strength Ratios DVAX's Dividend Payout Ratio
DVAX's Roa DVAX's Inventory Turnover Ratio DVAX's Growth Rates DVAX's Dividend Comparisons



Companies with similar EPS from Cont. Operations drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %EPS from Cont. Operations for the quarter ending Sep 30 2023
Shockwave Medical Inc -2.06%$ -2.062 
Corcept Therapeutics Inc-3.13%$ -3.125 
Viatris Inc -3.45%$ -3.448 
Henry Schein Inc-3.64%$ -3.636 
Universal Health Services Inc -3.97%$ -3.968 
National Research Corporation-5.88%$ -5.882 
Mettler toledo International Inc -5.99%$ -5.990 
The Pennant Group Inc -6.25%$ -6.250 
Quest Diagnostics Inc-9.55%$ -9.545 
Charles River Laboratories International inc -10.53%$ -10.526 
Carlisle Companies Incorporated-11.00%$ -10.998 
Zimmer Biomet Holdings Inc -15.22%$ -15.217 
Stryker Corp-15.74%$ -15.741 
Tenet Healthcare Corp-18.18%$ -18.182 
Amgen Inc -19.45%$ -19.451 
Hologic Inc-22.07%$ -22.070 
Regeneron Pharmaceuticals Inc -22.99%$ -22.989 
Zynex inc -23.08%$ -23.077 
Dariohealth Corp -23.44%$ -23.438 
Pediatrix Medical Group Inc -25.71%$ -25.714 
Entera Bio Ltd -27.27%$ -27.273 
U S Physical Therapy Inc-29.17%$ -29.167 
Avantor Inc -36.00%$ -36.000 
Ufp Technologies Inc -40.70%$ -40.698 
Biomx Inc -43.48%$ -43.478 
Laboratory Corporation Of America Holdings-45.78%$ -45.780 
Pacific Health Care Organization Inc -50.00%$ -50.000 
Royalty Pharma Plc-50.00%$ -50.000 
Staar Surgical Company-52.38%$ -52.381 
Repligen Corp-54.79%$ -54.795 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com